Skip to main content

Table 2 Immune oncologic agents and dosing

From: Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer

Drug

Manufacturer

Dose

BN-MVA-Brachyury (prime doses)

Bavarian Nordic

2.0 × 108 infectious units s.c. every 2 weeks for 2 doses

BN-Brachyury-FPV (boost doses)

Bavarian Nordic

1 × 109 infectious units s.c. begin 2 weeks following the 2nd priming dose, continued every 2 weeks for 6 doses, then every 3 months for 2 years

M7824

EMD Serono, Inc.

1200 mg i.v. every 2 weeks

ALT-803

Altor BioScience

Given s.c. every 2 weeks (see Table 2)

Epacadostat

Incyte, Corp.

100 mg by mouth twice daily